$XBI $94.65 | -1.04%
Covid Updates
$ENTA -2.1% Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19. source
Pipeline Updates
$MRKR -7.7% MARKER THERAPEUTICS ANNOUNCES CLINICAL PROGRAM UPDATES AND PIPELINE EXPANSION source
$GILD +0.9% New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor source
$ACAD +0.8% Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis. source
$JAGX -4.0% Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs. source
$SPRO -3.7% Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital. source
$HZNP -0.5% New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD). source
$RYTM -2.4% Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS). source
$OTIC -3.7% Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting. source
$IFRX -4.1% InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma. source
$SAGE -17.5% Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD. source
$GBT +7.5% European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older. source
$AZN +0.9% Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus. source
Business Updates
$ADIL -0.9% Adial Pharmaceuticals Announces Closing of $10 Million Financing. source
$CYTK -2.3% Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease. source
$EQ +3.9% Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates. source
$BNTX +1.3% BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa. source
$MRNA +0.5% Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years. source
$MRNA +0.5% Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries. source
Posted by FS/JM
Comentarios